High expression of THY1 in ECs is associated with poor prognosis across various cancers 53, and the increase in vascular ECs post-treatment likely provides essential blood supply to residual tumors, which may contribute to prostate cancer recurrence following hormonal therapy. This evidence concerns the gene THY1 and prostate carcinoma.